BioCardia, Inc. (BCDA): who owns it and who trades it
As of Nov 16, 2026, BCDA insiders reported 34 purchases worth $170K in the last 12 months. The largest buyer was Simon H Stertzer (Director), with $104K. 1 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling BioCardia
From the latest filingsOverall: about as much buying as selling. Famous investors mostly sold. Insiders mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Insider trades
In the last 12 months, BCDA insiders reported $170K of open-market purchases and $0 of sales.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Oct 16, 2026 | Peter Altman | CEO | Purchase | 300 | $0.95 | $285 | Form 4 |
| Oct 15, 2026 | Peter Altman | CEO | Purchase | 200 | $0.95 | $190 | Form 4 |
| Sep 29, 2026 | Peter Altman | CEO | Purchase | 1,000 | $1.03 | $1K | Form 4 |
| Sep 23, 2026 | Peter Altman | CEO | Purchase | 1,900 | $1.05 | $2K | Form 4 |
| Sep 3, 2026 | Peter Altman | CEO | Purchase | 800 | $1.09 | $872 | Form 4 |
| Aug 17, 2026 | Peter Altman | CEO | Purchase | 5,400 | $0.93 | $5K | Form 4 |
| Aug 13, 2026 | Peter Altman | CEO | Purchase | 1,900 | $0.92 | $1.7K | Form 4 |
| Jul 29, 2026 | Peter Altman | CEO | Purchase | 5,000 | $0.78 | $3.9K | Form 4 |
| Jul 17, 2026 | Peter Altman | CEO | Purchase | 500 | $0.83 | $415 | Form 4 |
| Jul 15, 2026 | Peter Altman | CEO | Purchase | 1,500 | $0.86 | $1.3K | Form 4 |
| Jul 14, 2026 | Peter Altman | CEO | Purchase | 2,800 | $0.88 | $2.5K | Form 4 |
| Jul 10, 2026 | Peter Altman | CEO | Purchase | 1,000 | $0.94 | $940 | Form 4 |
| Jul 9, 2026 | Peter Altman | CEO | Purchase | 1,000 | $0.90 | $900 | Form 4 |
| Jul 8, 2026 | Peter Altman | CEO | Purchase | 5,500 | $0.97 | $5.3K | Form 4 |
| Jul 8, 2026 | Peter Altman | CEO | Purchase | 5,400 | $0.96 | $5.2K | Form 4 |
| Jun 23, 2026 | Simon H Stertzer | Director | Purchase | 39,000 | $1.00 | $39K | Form 4 |
| Jun 22, 2026 | Simon H Stertzer | Director | Purchase | 70,200 | $0.92 | $64.6K | Form 4 |
| Jun 18, 2026 | Peter Altman | CEO | Purchase | 800 | $0.96 | $768 | Form 4 |
| Jun 17, 2026 | Peter Altman | CEO | Purchase | 1,500 | $0.85 | $1.3K | Form 4 |
| Jun 9, 2026 | Peter Altman | CEO | Purchase | 5,000 | $0.85 | $4.2K | Form 4 |
| May 20, 2026 | Peter Altman | CEO | Purchase | 1,500 | $0.92 | $1.4K | Form 4 |
| May 19, 2026 | Peter Altman | CEO | Purchase | 200 | $0.95 | $190 | Form 4 |
| May 18, 2026 | Peter Altman | CEO | Purchase | 5,700 | $0.92 | $5.2K | Form 4 |
| May 15, 2026 | Peter Altman | CEO | Purchase | 5,100 | $1.02 | $5.2K | Form 4 |
| Apr 29, 2026 | Peter Altman | CEO | Purchase | 5,000 | $1.11 | $5.6K | Form 4 |
| Apr 21, 2026 | Peter Altman | CEO | Purchase | 400 | $1.23 | $492 | Form 4 |
| Apr 20, 2026 | Peter Altman | CEO | Purchase | 600 | $1.23 | $738 | Form 4 |
| Mar 25, 2026 | Peter Altman | CEO | Purchase | 300 | $1.22 | $366 | Form 4 |
| Mar 24, 2026 | Peter Altman | CEO | Purchase | 600 | $1.24 | $744 | Form 4 |
| Feb 4, 2026 | Peter Altman | CEO | Purchase | 5,000 | $1.13 | $5.6K | Form 4 |
| Jan 21, 2026 | Peter Altman | CEO | Purchase | 300 | $1.34 | $402 | Form 4 |
| Jan 20, 2026 | Peter Altman | CEO | Purchase | 600 | $1.32 | $792 | Form 4 |
| Dec 17, 2025 | Peter Altman | CEO | Purchase | 900 | $1.30 | $1.2K | Form 4 |
| Dec 16, 2025 | Peter Altman | CEO | Purchase | 200 | $1.37 | $274 | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Simon H Stertzer | Director | $104K | – | Jun 23, 2026 |
| Peter Altman | President and CEO, Director | $66.1K | – | Oct 16, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
BCDA short interest
Low short interest. 4.9% of BCDA shares are sold short: about 1 share in 21. Over the last 12 reports the number of shares short went up 199%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 735,104 BCDA shares were sold short, 4.9% of the shares outstanding, up 8.4% from the report before. At the average daily volume of 116,810 shares, buying them all back would take about 6.3 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 735,104 | 4.86% | +8% | 116,810 | 6.3 |
| Oct 15, 2026 | 678,398 | 4.48% | +10% | 134,256 | 5.0 |
| Sep 30, 2026 | 619,162 | 4.09% | -28% | 487,811 | 1.3 |
| Sep 15, 2026 | 863,665 | 5.70% | -14% | 187,434 | 4.6 |
| Aug 31, 2026 | 1.01M | 6.65% | -2% | 219,231 | 4.6 |
| Aug 14, 2026 | 1.03M | 6.80% | -7% | 298,017 | 3.5 |
| Jul 31, 2026 | 1.11M | 10.12% | -18% | 218,292 | 5.1 |
| Jul 15, 2026 | 1.34M | 12.27% | +261% | 509,766 | 2.6 |
| Jun 30, 2026 | 371,795 | 3.40% | -15% | 1.60M | 1.0 |
| Jun 15, 2026 | 438,565 | 4.01% | +33% | 14.59M | 1.0 |
| May 29, 2026 | 329,380 | 3.01% | +34% | 120,914 | 2.7 |
| May 15, 2026 | 245,775 | 2.25% | +48% | 551,652 | 1.0 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
BioCardia company events
BioCardia filed 30 reports on Form 8-K in the last 12 months, 4 of them about an important change (leadership, listing). The latest was on Nov 6, 2026.
- Nov 6, 2026AnnouncementBioCardia, Inc. issued a press release announcing completion of clinical consultation process with Japan's PMDA for CardiAMP Cell Therapy System, advancing toward submission of marketing approval application. Filing
- Oct 19, 2026AnnouncementBioCardia, Inc. issued a press release announcing FDA Acceptance of De Novo Pre-Submission Package for Helix Catheter Marketing Clearance FDA Substantive Review and Meeting Expected this Quarter. Filing
- Oct 7, 2026AnnouncementBioCardia, Inc. issued a press release reporting that BioCardia presents CardiAMP HF II Trial design at Heart Failure Society of America Annual Scientific Meeting. Filing
- Oct 1, 2026AnnouncementBioCardia, Inc. issued a press release that reported it has completed its revised Pre-Submission to FDA Center for Devices and Radiological Health (CDRH) under its Q-Submission program for the approval of its Helix Catheter for therapeutic and diagnostic agent delivery to the heart. Filing
- Sep 23, 2026AnnouncementBioCardia, Inc. issued a press release that confirms timing and provides an update on FDA Helix Pre-Submission and PMDA CardiAMP HF Shonin Submission. Filing
- Sep 21, 2026AnnouncementAs previously disclosed, on August 19, 2026, BioCardia, Inc. received a letter from the Listing Qualifications Department of The NASDAQ Stock Market, LLC indicating that, for the last 30 consecutive business days, the minimum price of the Company’s common stock had been below the $1.00 per share… Filing
- Sep 10, 2026AnnouncementBioCardia, Inc. issued a press release announcing that Peter Altman, Ph.D., President and Chief Executive Officer, will present at the H.C. Wainwright 28th Annual Global Investment Conference. Filing
- Aug 24, 2026AnnouncementShared information with investors. Filing
- Aug 21, 2026ListingBioCardia, Inc. received a written notice from the Nasdaq Listing Qualifications staff of The Nasdaq Stock Market LLC indicating that, for the last 30 consecutive business days, the minimum bid price of the Company’s common stock had been below the $1.00 per share minimum requirement for continued… Filing
- Aug 12, 2026ResultsReleased financial results. Filing
- Jun 18, 2026AnnouncementShared information with investors. Filing
- Jun 12, 2026ListingAs previously disclosed on that certain Current Report on Form 8-K filed with the Securities and Exchange Commission on April 15, 2026, on April 10, 2026, BioCardia, Inc. received a notification letter from the Nasdaq Listing Qualifications Staff of The Nasdaq Stock Market LLC notifying the Company… Filing
- Jun 8, 2026AnnouncementBioCardia, Inc. issued a press release announcing that the Company sold 3,509,604 shares at an average price of $1.279 on Friday, June 5, 2026. Filing
- Jun 5, 2026AnnouncementShared information with investors. Filing
- May 28, 2026AnnouncementShared information with investors. Filing
- May 21, 2026AnnouncementShared information with investors. Filing
- May 15, 2026ResultsReleased financial results. Filing
- May 8, 2026AnnouncementShared information with investors. Filing
- Apr 28, 2026AnnouncementBioCardia, Inc. issued a press release announcing the allowance of Japanese Patent, “Target Site Selection, Entry, and Update with Automatic Remote Image Annotation.” This patent adds further protection to BioCardia’s proprietary Heart3D™ Fusion Imaging (Heart3D) software intended for treatment… Filing
- Apr 20, 2026AnnouncementShared information with investors. Filing
- Apr 15, 2026ListingBioCardia, Inc. received written notice from The Nasdaq Stock Market LLC notifying the Company that, based on the Company’s stockholders’ equity of $895,000 as of December 31, 2025, it is no longer in compliance with the minimum stockholders’ equity requirement of $2.5 million for continued listing… Filing
- Apr 2, 2026AnnouncementShared information with investors. Filing
- Mar 24, 2026ResultsReleased financial results. Filing
- Mar 17, 2026AnnouncementBioCardia, Inc. issued a press release announcing that the FDA has accepted its pre-submission package for the approval of its Helix Transendocardial Delivery Catheter intended for intramyocardial therapeutic and diagnostic agent delivery. Filing
- Mar 3, 2026AnnouncementShared information with investors. Filing
- Feb 10, 2026AnnouncementBioCardia, Inc. issued a press release announcing it has completed its Pre-Submission under the Q-Submission program to the U.S. Food and Drug Administration for the approval of its Helix Transendocardial Delivery Catheter for intramyocardial therapeutic and diagnostic agent delivery. Filing
- Feb 3, 2026AnnouncementBioCardia, Inc. issued a press release announcing that echocardiography data from the CardiAMP Cell Therapy for the treatment of heart failure has been accepted for Late Breaking Clinical Trial Oral Presentation at the Technology and Heart Failure Therapeutics (THT) Meeting, which takes place March… Filing
- Dec 16, 2025AnnouncementShared information with investors. Filing
- Dec 3, 2025LeadershipThe Board of Directors of BioCardia, Inc. appointed Marvin Slosman as a member of the Board, with an initial term beginning immediately and expiring at BioCardia’s 2028 Annual Meeting of Shareholders, or until his successor is duly elected and qualified. Filing
- Nov 24, 2025AnnouncementBioCardia, Inc. issued a press release announcing the appointment of Farhan Shahab as Vice President of Quality. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
BioCardia financials
Famous investors that hold BCDA
1 of the 50 well-known investors we track reported holding BCDA in their latest 13F filing. The largest position is Ken Griffin's, worth $16.9K.
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Griffin · Citadel Advisors | Q3 2026 | 16,691 | $16.9K | 0.0% | -27% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named BCDA in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 10, 2026 | Thomas A. Satterfield, Jr. | 13G/A | 9.9% |
| Nov 10, 2026 | Thomas A. Satterfield, Jr. | 13G/A | 9.9% |
Questions about BioCardia, Inc. (BCDA) stock
Are BCDA insiders buying or selling?
In the last 12 months, BCDA insiders reported 34 open-market purchases worth $170K and no sales. The latest trade was on Oct 16, 2026. See every trade.
What is the short interest in BCDA?
As of Oct 30, 2026, 735,104 BCDA shares were sold short, 4.9% of the shares outstanding, up 8.4% from the report before. At the average daily volume of 116,810 shares, buying them all back would take about 6.3 trading days (days to cover). See the history.
Which famous investors hold BCDA?
1 of the 50 well-known investors we track reported BCDA in their latest 13F filing, including Ken Griffin. The largest position is worth $16.9K. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.